13th Annual Global Embolization Symposium & Technologies
Purpose : To present 3-year safety and efficacy data for prostatic artery embolization (PAE) using 100-300μm Embospheres to treat urinary retention from benign prostatic hyperplasia (BPH).
Material and Methods : 46 urinary retention patients underwent PAE with 100-300μm Embospheres from May 2013 through July 2018. 2 patients wanting catheters left in and 1 technical failure were excluded. Subjects (n=43, mean age=78.1±8.5, mean Charlson comorbidity index=4.5±1.7, mean gland size=204±98mL) had mean retention duration=162±148 days. After PAE, any voiding trial failures (void efficiency <60%) at 1 month were repeated at 2 months. International Prostate Symptom Score (IPSS), Quality of Life score (QOL), and post-void residual (PVR) were recorded at 3, 6, 12, 24, 36 months and compared to baseline with Wilcoxon signed-rank tests or T-tests. Adverse events up to 90 days were recorded.
Results : 33/38(87%) of patients eligible for follow-up had successful catheter removal (mean time to removal=39.4±34.3 days), with similar catheter-free rate sustained for 3 years. 2 patients began self-catheterizing (CIC). 3 patients failed voiding. For follow-up eligible patients, Figure 1 shows voiding status and Figure 2 shows mean IPSS, QOL and PVR after catheter removal, at 3, 6, 12, 24, 36 months. 6/43(14%) patients had Grade-II catheter-related urinary infections, 1 died of unrelated warfarin toxicity.
Conclusions : 83% of patients remained catheter-free with sustained satisfactory voiding at 3 years. PAE with 100-300μm Embospheres treated urinary retention safely and effectively, similar to other series with larger particles and shorter follow-up.